Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Core Insights - The FDA has cleared the IND application for UX016, a small molecule prodrug of sialic acid, aimed at treating GNE myopathy, a rare neuromuscular disorder [1][3] - The UX016 program is externally funded by a patient group and will include a Phase 1/2 study expected to start in the second half of 2026 [1][3] Company Overview - Ultragenyx Pharmaceutical Inc. is focused on developing therapies for rare and ultra-rare genetic diseases, with a commitment to addressing high unmet medical needs [6][7] - The company has a diverse portfolio of approved medicines and treatment candidates, emphasizing time- and cost-efficient drug development [7] Product Details - UX016 is designed to improve the delivery of sialic acid to muscle tissues, potentially restoring sialylation of muscle glycoproteins and glycolipids, which may slow disease progression [5] - The planned Phase 1/2 study will enroll approximately 24 adults aged 18 to 55 with GNE myopathy, evaluating safety, efficacy, and pharmacokinetics [3][4] Disease Context - GNE myopathy is a rare, debilitating condition affecting around 10,000 individuals in commercially accessible regions, with no approved therapies currently available in the U.S. [4]